FDA Grants ODD to Utidelone Capsules For Treatment of Gastric Cancer
The orphan drug designation is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.
Source: pharmacytimes.com
Stay updated with breaking news from Utidelone Capsule. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The orphan drug designation is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.
/PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company...